NTLA Add to watchlist $14.94 +0.16 (+1.08%) Last updated: Apr 16, 2026 00:48
52-Week Range
$14.94
$6.73 $14.94 $28.25

Fundamentals Overview

Intellia Therapeutics, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/B 2.41 P/S 26.08

Risk (Beta)

1.99 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 55% confidence Risk: High Volatility — Beta 1.99. Consider smaller position size due to higher beta.

Supporting (Buy):

3M vs S&P 500: +30% · 3M vs Healthcare sector: +36.8%

Pressures (Sell):

Sentiment weakening (7 downgrades) · Beta 1.99 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$1.76B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$6.73 - $28.25
Volume vs Avg
N/A
Beta
1.99

About

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute mye...
Sector: Healthcare
Headquarters: US
Employees: 403
IPO Date: May 2016
Beta: 1.99 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: C+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 12, Equal Weight: 3, Hold: 1, In Line: 1, Market Outperform: 3, Market Perform: 1, Neutral: 1, Outperform: 1, Overweight: 2, Peer Perform: 1, Sector Perform: 3, Underweight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-17.19; current price is $14.94. That’s a -215.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 2.41
P/S (TTM) 26.08
Liquidity & enterprise
Current Ratio (TTM) 5.08
Quick Ratio (TTM) 5.08
Cash Ratio (TTM) 1.5
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -6.1%
Gross margin (TTM) -25.55%
Operating margin (TTM) -6.52%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for NTLA.

Analyst Sentiment at a Glance

C+ Sentiment Weakening
Buy 12Equal Weight 3Hold 1In Line 1Market Outperform 3Market Perform 1Neutral 1Outperform 1Overweight 2Peer Perform 1Sector Perform 3Underweight 1
1 upgrade, 7 downgrades
Price Target Consensus
Current $14.94
Median $14.50
Consensus $19.38
Low consensus $7.00
High consensus $48.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Jones Trading upgrade Hold Buy 2026-03-04
Wells Fargo maintain Equal Weight Equal Weight 2026-03-03
Canaccord Genuity maintain Buy Buy 2026-03-03
HC Wainwright & Co. maintain Buy Buy 2026-03-03
Citizens maintain Market Outperform Market Outperform 2026-03-03
RBC Capital maintain Sector Perform Sector Perform 2026-03-03
Leerink Partners maintain Outperform Outperform 2026-03-03
Chardan Capital maintain Buy Buy 2026-03-02
Chardan Capital maintain Buy Buy 2026-02-27
HC Wainwright & Co. maintain Buy Buy 2026-01-28
Wolfe Research downgrade Outperform Peer Perform 2025-11-12
Evercore ISI Group downgrade Outperform In Line 2025-11-11
Jones Trading downgrade Buy Hold 2025-11-11
Truist Securities maintain Buy Buy 2025-11-10
HC Wainwright & Co. maintain Buy Buy 2025-11-10
Citizens maintain Market Outperform Market Outperform 2025-11-07
Chardan Capital maintain Buy Buy 2025-11-07
Wedbush maintain Neutral Neutral 2025-11-07
Wells Fargo maintain Equal Weight Equal Weight 2025-11-07
JP Morgan downgrade Neutral Underweight 2025-11-07
RBC Capital maintain Sector Perform Sector Perform 2025-11-07
Barclays maintain Overweight Overweight 2025-11-07
HC Wainwright & Co. maintain Buy Buy 2025-10-30
RBC Capital downgrade Outperform Sector Perform 2025-10-28
Barclays maintain Overweight Overweight 2025-10-28
JMP Securities maintain Market Outperform Market Outperform 2025-10-28
Bernstein downgrade Outperform Market Perform 2025-10-28
Wells Fargo downgrade Overweight Equal Weight 2025-10-28
HC Wainwright & Co. maintain Buy Buy 2025-10-27
Chardan Capital maintain Buy Buy 2025-10-27